GLP-1 Weight-Loss Protocol
The evidence-based GLP-1 progression — start semaglutide, switch to tirzepatide if needed, with titration schedule and side-effect mitigation.
TL;DR
Start semaglutide at 0.25 mg weekly and titrate up every 4 weeks toward the 2.4 mg maintenance dose. If you plateau before reaching weight-loss goals, transition to tirzepatide (2.5 mg weekly start, titrating to 10–15 mg). The dual-agonist mechanism produces ~20.9% body weight loss at 72 weeks vs ~14.9% for semaglutide.
Compounds
Semaglutide → Tirzepatide
Route
Weekly subcutaneous
Starting dose (Sema)
0.25 mg weekly × 4 wk
Max dose (Sema)
2.4 mg weekly
Starting dose (Tirz)
2.5 mg weekly × 4 wk
Max dose (Tirz)
15 mg weekly
Who this protocol is for
- BMI ≥ 27 with weight-related comorbidity, or BMI ≥ 30
- Type 2 diabetes (both compounds FDA-approved for T2D)
- Plateau on lifestyle intervention alone after 6+ months
- Sleep apnea + obesity (Zepbound has FDA approval for this combo)
- Cardiovascular risk reduction goal (semaglutide FDA-approved for CV outcomes)
Why this stack
Semaglutide is the first-line choice for most patients. It has the longer real-world safety dataset (8+ years), broader insurance coverage, FDA-approved cardiovascular indications, and an oral form (Rybelsus) for patients who can't tolerate weekly injections.
Tirzepatide is the dual-agonist next-step. It hits both the GLP-1 and the GIP receptor — that second mechanism appears to amplify satiety signaling and preferentially mobilize fat mass over lean mass. SURPASS-2 (head-to-head vs semaglutide) showed greater HbA1c reduction and greater weight loss at every dose comparison.
Don't stack them — both saturate the GLP-1 receptor, so adding tirzepatide to semaglutide gives you double side effects with no additional benefit. The correct sequence is semaglutide first, switch to tirzepatide if plateau occurs before goal.
Phase schedule
Phase 1
Weeks 1–16: Semaglutide titration
Standard semaglutide dose escalation. Move up one dose level every 4 weeks. If GI side effects are severe, stay at the current dose for an additional 4 weeks before escalating.
- Weeks 1–4: 0.25 mg weekly subQ.
- Weeks 5–8: 0.5 mg weekly subQ.
- Weeks 9–12: 1.0 mg weekly subQ.
- Weeks 13–16: 1.7 mg weekly subQ.
Phase 2
Weeks 17+: Semaglutide maintenance OR switch decision
Move to 2.4 mg/week. Evaluate at week 20: if you're on track for the target weight loss, stay on semaglutide. If you've plateaued >4 weeks below target, plan the tirzepatide switch.
- Weeks 17–20: 2.4 mg weekly subQ (max dose).
- Continue if: still losing ≥0.5 lb/week.
- Switch if: weight has plateaued 4+ weeks and you're not at goal.
Phase 3
Switch protocol: Semaglutide → Tirzepatide
Complete your current semaglutide week, wait one week (no injection), then start tirzepatide at 2.5 mg/week. Do not stack — both saturate the GLP-1 receptor.
- Final semaglutide week: 2.4 mg.
- Washout: 1 week, no injection.
- Tirzepatide start: 2.5 mg weekly × 4 wk.
Phase 4
Tirzepatide titration (post-switch)
Same 4-week titration cadence as semaglutide. Continue escalation until weight-loss goal or until intolerance plateaus you below max dose.
- Weeks 1–4 (post-switch): 2.5 mg.
- Weeks 5–8: 5 mg.
- Weeks 9–12: 7.5 mg.
- Weeks 13–16: 10 mg.
- Weeks 17+: 12.5–15 mg (target maintenance).
Phase 5
Maintenance + taper consideration
Once at goal weight: most protocols continue the lowest effective dose indefinitely to prevent rebound. Some patients trial a slow taper after 12 months of maintenance, accepting that weight regain is common when GLP-1s are fully discontinued.
- Maintain on lowest effective dose long-term.
- Optional taper: drop one dose level every 8 weeks after 12 months at goal.
- Re-escalate immediately if weight regain >5% body weight.
Step-by-step setup
- Confirm prescribing eligibility with a licensed clinician. Both compounds are prescription drugs in the US, EU, and most jurisdictions. Telehealth platforms offering GLP-1s typically require BMI ≥ 27 plus comorbidity or BMI ≥ 30 alone.
- Source pharmaceutical-grade product. Brand-name (Wegovy, Ozempic, Zepbound, Mounjaro) is the gold standard. If using compounded versions, verify the pharmacy has HPLC/mass-spec verification and FDA-503A or 503B compliance.
- Baseline labs + symptom inventory. Pre-protocol panel: HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel, TSH. Document baseline weight, body composition (DEXA if accessible), waist circumference, BP, and any GI baseline issues.
- Inject weekly, same day each week. Subcutaneous in the abdomen, thigh, or upper arm. Rotate sites weekly. Set a calendar reminder — consistency at the same weekly cadence keeps the dose-effect predictable.
- Manage GI side effects proactively. Eat smaller meals, lower-fat foods, increase fiber and water. Anti-nausea pharmaceuticals (ondansetron, prochlorperazine) are reasonable if symptoms are intolerable in the first 1–2 weeks of a new dose level.
- Track weight weekly + measurements monthly. Weigh weekly at the same time of day. Track waist + hip monthly. Re-test HbA1c and lipid panel at month 3 and month 6 — improvements often outpace weight loss.
- Preserve muscle mass. GLP-1 weight loss is partially lean-mass loss if you don't lift. Maintain resistance training 2–3× weekly throughout. Hit 1.2–1.6 g protein per kg body weight daily — appetite suppression makes this harder than it sounds.
Expected outcomes
- Semaglutide max-dose protocols: mean ~14.9% body weight loss at 68 weeks (STEP-1)
- Tirzepatide max-dose protocols: mean ~20.9% body weight loss at 72 weeks (SURMOUNT-1)
- HbA1c reduction of 1.5–2.4% in T2D patients
- Significant reduction in cardiovascular events (SUSTAIN-6, SELECT) for semaglutide
- Improved sleep apnea severity (Zepbound, SURMOUNT-OSA) for tirzepatide
Safety + side-effect profile
Both compounds share the same boxed warning for medullary thyroid carcinoma (rodent-data-derived) and the same GI-dominant side-effect profile. Side effects are highly dose-titration-dependent — slow titration is the single biggest mitigator.
- Nausea, vomiting, diarrhea, constipation — most common, usually transient at each new dose level.
- Pancreatitis: rare but serious. Severe persistent abdominal pain → stop immediately, seek care.
- Gallbladder disease: increased risk especially with rapid weight loss. Manage with slow titration.
- Boxed warning: medullary thyroid carcinoma + MEN2 — contraindicated.
- Pregnancy: not appropriate. 2-month washout before conception.
- Hypoglycemia risk is low as monotherapy; higher when combined with insulin or sulfonylureas.
- Watch for muscle/lean mass loss — resistance training + adequate protein are mandatory.
Frequently asked
Why start semaglutide instead of tirzepatide?
Three reasons: (1) Semaglutide has the longer real-world safety record (8+ years post-marketing). (2) Insurance coverage is broader. (3) Many patients reach their weight-loss goals on semaglutide alone — switching to tirzepatide is unnecessary in those cases. Start with the lower-mechanism option and escalate only if you plateau.
When should I switch from semaglutide to tirzepatide?
Standard criteria: you've been on the max semaglutide dose (2.4 mg/week) for at least 4 weeks AND your weight has plateaued ≥4 weeks AND you're still meaningfully short of your weight-loss goal. If all three apply, the switch typically produces an additional 6–10% body weight loss.
Can I take semaglutide and tirzepatide together?
No. Both saturate the GLP-1 receptor, so stacking gives you double the GI side effects with no additional weight-loss benefit. The correct move is to switch, not stack. Allow a 1-week washout when transitioning to avoid stacked half-lives.
How long do I stay on a GLP-1?
Most protocols treat GLP-1s as long-term metabolic medications, similar to statins or blood pressure medication. Weight regain when discontinued is common — typically 60–70% of lost weight returns within 12 months. Patients who tolerate the drug well usually stay on the lowest effective maintenance dose indefinitely.
What about compounded semaglutide and tirzepatide?
Compounded versions can be legitimate during shortages or for cost reasons, but quality varies. Verify the compounding pharmacy is FDA-503A or 503B compliant and has third-party HPLC/mass-spec verification of each batch. Brand-name product is the safest default when available and affordable.
Cited research
Wilding et al. — Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021.
Jastreboff et al. — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022.
Frías et al. — Tirzepatide versus semaglutide once weekly in T2D (SURPASS-2). NEJM 2021.
Marso et al. — Semaglutide and cardiovascular outcomes (SUSTAIN-6). NEJM 2016.
Lincoff et al. — Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 2023.
Personalize this protocol with the Coach
The Coach adapts dose, timing, and side-effect mitigation to your bloodwork, body comp, and goals — and outputs a cited PDF protocol card you can take to your doctor.
Ask the Coach